Experimental Drug Doubles Survival Time in Pancreatic Cancer Patients

Pancreatic cancer remains one of the most lethal cancers known, with a five-year survival rate under 15% and very few treatment breakthroughs in decades. That landscape may be shifting with the emergence of daraxonrasib, an experimental drug developed by biotech firm Revolution Medicines that is now being shipped to patients under an FDA early access program.

The drug's momentum comes from a Phase 3 clinical trial whose results were reported in mid-April. Patients treated with daraxonrasib survived nearly twice as long as those treated with standard chemotherapy. In a disease where incremental improvements are celebrated, a near-doubling of survival time is being called unprecedented by clinicians and researchers in the field.

Revolution Medicines CEO Mark Goldsmith confirmed the shipments at a STAT-hosted event alongside the American Society of Clinical Oncology annual meeting in Chicago. The early access program allows patients to receive the drug before it receives formal FDA approval, a pathway typically reserved for cases where preliminary evidence of benefit is compelling and the unmet medical need is severe — both of which apply here.

For the longevity-conscious reader, pancreatic cancer represents one of the starkest examples of how a single diagnosis can collapse healthspan and lifespan simultaneously. Advances in treatment directly extend both survival and quality of remaining life. Daraxonrasib, if approved, could become a standard-of-care option for one of medicine's hardest-to-treat cancers.

Important caveats remain: the drug is not yet approved, full Phase 3 data have not been published in peer-reviewed form, and long-term safety data are still emerging. Access is currently limited through physician referral under the early access framework. Patients and caregivers should consult oncologists about eligibility. The coming months will be critical as the FDA reviews the data and a formal approval decision approaches.